Will DAPA-HF Turn the Tide on Heart Failure? Will DAPA-HF Turn the Tide on Heart Failure?

The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Expert Column Source Type: news